153 related articles for article (PubMed ID: 28595169)
1. The Addition of Target Therapy to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review.
Benevento I; De Felice F; Musio D; Tombolini V
Chemotherapy; 2017; 62(5):314-322. PubMed ID: 28595169
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Velenik V; Ocvirk J; Oblak I; Anderluh F
Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
[TBL] [Abstract][Full Text] [Related]
3. The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer.
Torino F; Sarmiento R; Gasparini G
Crit Rev Oncol Hematol; 2013 Sep; 87(3):283-305. PubMed ID: 23478150
[TBL] [Abstract][Full Text] [Related]
4. Combined-modality therapy for rectal cancer: future prospects.
Czito BG; Willett CG; Bendell JC
Clin Colorectal Cancer; 2007 Sep; 6(9):625-33. PubMed ID: 17945034
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary Management of Locally Advanced Rectal Cancer--An Evolving Landscape?
Lee M; Gibbs P; Wong R
Clin Colorectal Cancer; 2015 Dec; 14(4):251-61. PubMed ID: 26210575
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D
Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395
[TBL] [Abstract][Full Text] [Related]
8. Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy.
Czito BG; Willett CG
Semin Radiat Oncol; 2011 Jul; 21(3):203-11. PubMed ID: 21645865
[TBL] [Abstract][Full Text] [Related]
9. The role of targeted agents in preoperative chemoradiation for rectal cancer.
Wadlow RC; Ryan DP
Cancer; 2010 Aug; 116(15):3537-48. PubMed ID: 20564106
[TBL] [Abstract][Full Text] [Related]
10. Panitumumab in Combination With Preoperative Radiation Therapy in Patients With Locally Advanced RAS Wild-type Rectal Cancer: Results of the Multicenter Explorative Single-Arm Phase 2 Study NEORIT.
Merx K; Martens UM; Kripp M; Hoehler T; Geissler M; Gaiser T; Mai S; Kienle P; Belle S; Plöger C; Hieber U; Wenz F; Post S; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):867-875. PubMed ID: 28870789
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
Bertolini F; Chiara S; Bengala C; Antognoni P; Dealis C; Zironi S; Malavasi N; Scolaro T; Depenni R; Jovic G; Sonaglio C; Rossi A; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):466-72. PubMed ID: 19004567
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Glynne-Jones R; Mawdsley S; Harrison M
Acta Oncol; 2010 Apr; 49(3):278-86. PubMed ID: 20180626
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
15. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer.
Sclafani F; Cunningham D
Future Oncol; 2014 Nov; 10(14):2243-57. PubMed ID: 25471037
[TBL] [Abstract][Full Text] [Related]
17. Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications.
Dellas K; Buller J; Görtz GJ; Richter M; Höhler T; Arnold D; Keck T; Dunst J; Zühlke H
Ann Surg Oncol; 2014 Apr; 21(4):1352-60. PubMed ID: 24306667
[TBL] [Abstract][Full Text] [Related]
18. Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer.
Gollins S
Colorectal Dis; 2010 Aug; 12 Suppl 2():2-24. PubMed ID: 20618363
[TBL] [Abstract][Full Text] [Related]
19. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life.
Kripp M; Wieneke J; Kienle P; Welzel G; Brade J; Horisberger K; Wenz F; Post S; Gencer D; Hofmann WK; Hofheinz RD
Eur J Surg Oncol; 2012 Jun; 38(6):472-7. PubMed ID: 22349986
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]